No CrossRef data available.
Article contents
P0190 - Small doses of new generation antipsychotic in severe panic disorder
Published online by Cambridge University Press: 16 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Panic is a frequent often chronic disorder characterised by short-lasting sudden burst of panic fear with cognitive and somatic symptoms.
Aim of study was to determine effect of addition atypical antipsychotic agent in treatment-refractory panic disorder.
Methods:
Ten patients suffernig from panic disorder according to DSMIV criteria, who were poor responders to standard therapy/ SSRI or SNRI AD/ were examined.The most common symptoms were fear of going crazy, losing control, dying, fainting with vegetative symptoms as palpitation, trembling, sweating, vertigo.Olanzapine, quetiapine or risperidon were added.
Results:
Objective global assessment measured by HAMA, CGI and Quality of Life Scale made before, two and four months after beginning of trial.Mild to significant improvement were recorded in seven patients related to reduced severity and number of attacks.Quetiapin then olanzapin showed best results.
Conclusion:
Recommended treatment approaches include cognitive-behavioural as well as pharmacotherapy. Disorder have significant implications on global functioning, quality of life, suicidal risk.Limitation of our study is small number of participants, but there is a sense to try addition atypical antipsychotic in refractory cases.
- Type
- Poster Session III: Panic Disorders
- Information
- European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S356
- Copyright
- Copyright © European Psychiatric Association 2008
You have
Access
Comments
No Comments have been published for this article.